A November publication from the Saudi Food and Drug Authority places medical-device manufacturing within the country's investment and technology-transfer strategy. Its account emphasises international standards, qualified technical managers and regulatory engagement. For overseas suppliers considering Saudi assembly, that policy support sits alongside product and factory approvals rather than replacing them.1
The authority describes an early-engagement pathway for innovative devices, intended to clarify requirements during development. It also acknowledges that advanced manufacturing needs specialised infrastructure and skilled workers. Those are stated conditions and ambitions for expansion, rather than evidence that all announced investment has already become saleable output.1
Manufacturing can span borders
The SFDA's manufacturing-path guidance, version dated 7 July 2025, covers design and production as well as assembly, packaging and labelling. It distinguishes full manufacture at a Saudi site, production divided between sites belonging to a manufacturer, and contracted work involving an independent overseas manufacturer.2
The guidance requires a manufacturer licence and a medical-device marketing authorisation for circulation, subject to specified exemptions. The licence also requires a certified quality management system under the specified ISO standard, from an accredited assessment body. Importing semi-finished devices for local manufacturing also requires an import permit. Applications for a free-sale certificate, used for exports, require the manufacturer licence and marketing authorisation among their supporting conditions. Moving a production stage therefore does not erase the separate approvals attached to components, facilities and finished devices.2
The commercial test goes beyond a factory label
Regulatory consultancy Basier's September assessment distinguishes an imported-device business from an assembly operation and a fuller manufacturing undertaking. It advises companies to compare total costs, including inventory, servicing and freight, rather than comparing local assembly only with a foreign factory's selling price.3
The consultancy also identifies supplier qualification, process validation, staff training and final-release responsibility as practical demands of assembly. Its suggested pilot measures defects and production performance before expansion. These are advisory tests of commercial readiness, not additional statutory thresholds. Basier explicitly cautions that localisation policy does not guarantee procurement preference, a contract award or sufficient demand for a particular product.3
An Arabic sector study by consultancy ALJDWA provides a broader industrial backdrop. Drawing on government announcements, it lists 176 medical-device and medical-supply factories in 2026. The count describes establishments across the sector; it does not identify which factories have secured export orders or received approval for a specific new device.4
The study presents the objective as:4
رفع تعقيد المنتج داخل المصانع
increasing product sophistication within factories.4
That distinction matters for evaluating technology transfer. More establishments and deeper production capabilities are different indicators, and a factory count cannot by itself demonstrate the latter. The next test is whether the proposed shift into more sophisticated products produces documented manufacturing capability and completed sales, beyond the investment and capacity indicators in the sector study.4